Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010; 126:2762-72; PMID:20104527
   PubMed Web of Science ®Google Scholar
• Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials. Expert Opin Investig Drugs 2014; 26:1-13.
   Google Scholar
• Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat 2013; 45:251-62; PMID:24453997; http://dx.doi.org/10.4143/crt.2013.45.4.251
   PubMed Web of Science ®Google Scholar
• Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004; 100:826-33; PMID:14770441; http://dx.doi.org/10.1002/cncr.20057
   PubMed Web of Science ®Google Scholar
• Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 2013; 4:e458; PMID:23328665; http://dx.doi.org/10.1038/cddis.2012.197
   PubMedGoogle Scholar
• Bayin NS, Modrek AS, Placantonakis DG. Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World J Stem Cells 2014; 6:230-8; PMID:24772249; http://dx.doi.org/10.4252/wjsc.v6.i2.230
   PubMedGoogle Scholar
• Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 2014; 5:64; PMID:24991467; http://dx.doi.org/10.4103/2152-7806.137196
   PubMedGoogle Scholar
• Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, Feun L. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights 2007; 2:119-28; PMID:21901069
   PubMedGoogle Scholar
• Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther 2009; 8:3223-33; PMID:19934275; http://dx.doi.org/10.1158/1535-7163.MCT-09-0794
   PubMed Web of Science ®Google Scholar
• Hering S, Sieg A, Kreikemeyer B, Fiedler T. Kinetic characterization of arginine deiminase and carbamate kinase from Streptococcus pyogenes M49. Protein Expr Purif 2013; 91:61-8; PMID:23867361; http://dx.doi.org/10.1016/j.pep.2013.07.002
   PubMed Web of Science ®Google Scholar
• Mullins CS, Schneider B, Stockhammer F, Krohn M, Classen CF, Linnebacher M. Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison. PLoS One 2013; 8:e71070; PMID:23951083; http://dx.doi.org/10.1371/journal.pone.0071070
   PubMedGoogle Scholar
• Mullins CS, Schubert J, Schneider B, Linnebacher M, Classen CF. Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. J Cancer Res Clin Oncol 2013; 139:1425-31; PMID:23749036; http://dx.doi.org/10.1007/s00432-013-1457-6
   PubMed Web of Science ®Google Scholar
• Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 2012; 106:1481-5; PMID:22472884; http://dx.doi.org/10.1038/bjc.2012.106
   PubMed Web of Science ®Google Scholar
• Klier U, Maletzki C, Göttmann N, Kreikemeyer B, Linnebacher M. Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cell Immunol 2011; 269:120-7; PMID:21463858; http://dx.doi.org/10.1016/j.cellimm.2011.03.014
   PubMed Web of Science ®Google Scholar
• Maletzki C, Klier U, Marinkovic S, Klar E, Andrä J, Linnebacher M. Host defense peptides for treatment of colorectal carcinoma – a comparative in vitro and in vivo analysis. Oncotarget 2014; 5:4467-79; PMID:24962950
   PubMedGoogle Scholar
• Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol 2011; 38 Suppl 4:S2-10; PMID:22078644; http://dx.doi.org/10.1053/j.seminoncol.2011.09.005
   PubMedGoogle Scholar
• Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007; 12:1395-403; PMID:18165616; http://dx.doi.org/10.1634/theoncologist.12-12-1395
   PubMed Web of Science ®Google Scholar
• Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007; 13:1045-52; PMID:17289901; http://dx.doi.org/10.1158/1078-0432.CCR-06-1261
   PubMed Web of Science ®Google Scholar
• Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18:7016-25; PMID:10597302; http://dx.doi.org/10.1038/sj.onc.1203176
   PubMed Web of Science ®Google Scholar
• Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19:5712-9; PMID:11126357; http://dx.doi.org/10.1038/sj.onc.1203963
   PubMed Web of Science ®Google Scholar
• Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010; 12:473-81; PMID:20406898
   PubMed Web of Science ®Google Scholar
• Briceño E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003; 14:e3.
   PubMedGoogle Scholar
• Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013; 133:1222-33; PMID:23436212; http://dx.doi.org/10.1002/ijc.28126
   PubMed Web of Science ®Google Scholar
• Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008; 68:9551-7; PMID:19010932; http://dx.doi.org/10.1158/0008-5472.CAN-08-2058
   PubMed Web of Science ®Google Scholar